Attorney General Marty Jackley Announces $105 Million Consumer Settlement with GlaxoSmithKline

Print PDF

Wednesday, June 4, 2014

PIERRE, S.D.- Attorney General Marty Jackley today announced a settlement that signals a major change in the way pharmaceutical sales teams are motivated and paid for the ultimate benefit of consumers. The Attorneys General have reached a $105 million settlement with GlaxoSmithKline, LLC to resolve allegations that GlaxoSmithKline unlawfully promoted its asthma drug, Advair®, and antidepressant drugs, Paxil® and Wellbutrin®. The Complaint and Consent Judgment filed today alleges that GlaxoSmithKline violated state consumer protection laws by misrepresenting the uses and qualities of these drugs. South Dakota's share of this settlement is $1,182,269.12.

"We are pleased to join this multistate settlement to ensure that consumers are better protected from unacceptable marketing practices. This settlement sends a clear message that these types of allegations will be taken very seriously," said Jackley.

The Consent Judgment also requires GlaxoSmithKline (GSK) to reform its marketing and promotional practices. Specifically, GSK shall not:

The Consent Judgment also requires GSK to continue its Patient First Program at least through March 2019. The Patient First Program reduces financial incentives for sales representatives to engage in deceptive marketing.